Kalytera Therapeutics

Pharmaceuticals

Multinational · United States

Kalytera Therapeutics is a Qatsrin-based multinational, established in 2014. Pharmaceuticals. The company has 1-10 employees.

2014
Founded
At a Glance
In the News

3 articles covered by sources including themarketherald.ca, www.marketwired.com, app.quotemedia.com.

themarketherald.ca · Apr 5, 2021
Kalytera Therapeutics Inc. (TSXV:KLY) completes name change to Claritas Pharmaceuticals, Inc.
Read article ↗
Frequently Asked Questions
What does Kalytera Therapeutics do?

Kalytera Therapeutics Inc is a clinical-stage pharmaceutical company developing next-generation cannabinoid therapeutics. Kalytera develops novel cannabinoid medicines for a range of medical needs with an initial focus on graft-versus-host disease (GvHD). Kalytera also develops a new class of proprietary cannabidiol (CBD) therapeutics. Kalytera acquired its GvHD program from Israel-based Talent Biotechs in early 2017 based on the results of Talents' four phase-2a clinical studies in the prevention and treatment of GvHD using CBD.

Where is Kalytera Therapeutics located?

Kalytera Therapeutics is based in Katzrin, Israel .

View Full Profile Classic View Website ↗